title: Enhancement of CYP3A4 activity in Hep G2 cells by lentiviral transfection of hepatocyte nuclear factor-1 alpha.
abstract: Human hepatoma cell lines are commonly used as alternatives to primary hepatocytes for the study of drug metabolism in vitro. However, the phase I cytochrome P450 (CYP) enzyme activities in these cell lines occur at a much lower level than their corresponding activities in primary hepatocytes, and thus these cell lines may not accurately predict drug metabolism. In the present study, we selected hepatocyte nuclear factor-1 alpha (HNF1α) from six transcriptional regulators for lentiviral transfection into Hep G2 cells to optimally increase their expression of the CYP3A4 enzyme, which is the major CYP enzyme in the human body. We subsequently found that HNF1α-transfected Hep G2 enhanced the CYP3A4 expression in a time- and dose-dependent manner and the activity was noted to increase with time and peaked 7 days. With a multiplicity of infection (MOI) of 100, CYP3A4 expression increased 19-fold and enzyme activity more than doubled at day 7. With higher MOI (1,000 to 3,000), the activity increased 8- to 10-fold; however, it was noted the higher MOI, the higher cell death rate and lower cell survival. Furthermore, the CYP3A4 activity in the HNF1α-transfected cells could be induced by CYP3A4-specific inducer, rifampicin, and metabolized nifedipine in a dose-dependent manner. With an MOI of 3,000, nifedipine-metabolizing activity was 6-fold of control and as high as 66% of primary hepatocytes. In conclusion, forceful delivery of selected transcriptional regulators into human hepatoma cells might be a valuable method to enhance the CYP activity for a more accurate determination of drug metabolism in vitro.
authors.affiliation: Institute of Biotechnology, National Taiwan University, Taipei, Taiwan.
authors.forename: Tsai-Shin
authors.initials: TS
authors.lastname: Chiang
authors.affiliation: School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan.
authors.forename: Kai-Chiang
authors.initials: KC
authors.lastname: Yang
authors.affiliation: Liver Disease Prevention and Treatment Research Foundation, Taipei, Taiwan.
authors.forename: Ling-Ling
authors.initials: LL
authors.lastname: Chiou
authors.affiliation: Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
authors.forename: Guan-Tarn
authors.initials: GT
authors.lastname: Huang
authors.affiliation: Institute of Biotechnology, National Taiwan University, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan.
authors.forename: Hsuan-Shu
authors.initials: HS
authors.lastname: Lee
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism*; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D057809:HEK293 Cells; D056945:Hep G2 Cells; D051538:Hepatocyte Nuclear Factor 1-alpha / Q000378:metabolism*; D006801:Humans; D016086:Lentivirus / Q000378:metabolism*; D009543:Nifedipine / Q000378:metabolism; D012293:Rifampin / Q000494:pharmacology; D014161:Transduction, Genetic; D014162:Transfection
chemical_list: D051538:Hepatocyte Nuclear Factor 1-alpha; D003577:Cytochrome P-450 Enzyme System; D051544:Cytochrome P-450 CYP3A; D009543:Nifedipine; D012293:Rifampin
references.citation: Curr Drug Metab. 2008 Jan;9(1):1-11
references.pmid: 18220566
references.citation: J Matern Fetal Neonatal Med. 2012 Apr;25(4):419-23
references.pmid: 21644845
references.citation: Biochem J. 2000 Apr 15;347(Pt 2):321-37
references.pmid: 10749660
references.citation: Clin Pharmacokinet. 2003;42(15):1331-57
references.pmid: 14674787
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):534-44
references.pmid: 17339138
references.citation: Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7500-2
references.pmid: 10852961
references.citation: Biomaterials. 2012 Jul;33(21):5187-97
references.pmid: 22541353
references.citation: Toxicol Sci. 2013 May;133(1):67-78
references.pmid: 23377618
references.citation: Science. 2004 Feb 27;303(5662):1378-81
references.pmid: 14988562
references.citation: Drug Metab Dispos. 2010 Mar;38(3):516-25
references.pmid: 20019244
references.citation: Toxicology. 2000 Nov 16;153(1-3):1-10
references.pmid: 11090943
references.citation: Toxicol In Vitro. 2012 Dec;26(8):1272-7
references.pmid: 22138474
references.citation: Biochim Biophys Acta. 2003 Feb 17;1619(3):223-34
references.pmid: 12573481
references.citation: Arch Pharm Res. 2005 Mar;28(3):249-68
references.pmid: 15832810
references.citation: Nat Rev Drug Discov. 2003 Jul;2(7):542-53
references.pmid: 12815380
references.citation: Breast Cancer Res. 2013 Nov 08;15(6):R107
references.pmid: 24207099
references.citation: Chem Res Toxicol. 2008 Jan;21(1):70-83
references.pmid: 18052394
references.citation: Hepatology. 2003 Apr;37(4):924-30
references.pmid: 12668988
references.citation: Toxicol Sci. 2012 Nov;130(1):106-16
references.pmid: 22843569
references.citation: Curr Drug Metab. 2007 Feb;8(2):185-94
references.pmid: 17305497
references.citation: Drug Metab Dispos. 2003 Jul;31(7):938-44
references.pmid: 12814972
references.citation: Genes Dev. 2000 Jan 15;14(2):152-7
references.pmid: 10652269
references.citation: Biochimie. 2012 Nov;94(11):2338-44
references.pmid: 22906825
references.citation: Drug Metab Dispos. 2010 Jun;38(6):988-94
references.pmid: 20228232
references.citation: Toxicol Sci. 2008 Jun;103(2):268-77
references.pmid: 18332045
references.citation: Xenobiotica. 2009 Mar;39(3):205-17
references.pmid: 19280519
references.citation: J Toxicol Sci. 2011 Oct;36(5):625-33
references.pmid: 22008537
references.citation: World J Gastroenterol. 2009 Jun 21;15(23):2817-33
references.pmid: 19533803
references.citation: Life Sci. 2003 May 30;73(2):141-9
references.pmid: 12738030
references.citation: PLoS One. 2011;6(7):e21780
references.pmid: 21760905
references.citation: J Pharmacokinet Biopharm. 1996 Oct;24(5):449-59
references.pmid: 9131484
references.citation: Curr Drug Metab. 2004 Dec;5(6):483-505
references.pmid: 15578943
references.citation: Expert Opin Drug Metab Toxicol. 2006 Apr;2(2):183-212
references.pmid: 16866607
references.citation: FEBS Lett. 1998 Jul 17;431(2):227-30
references.pmid: 9708908
references.citation: Mol Endocrinol. 2000 Jan;14(1):27-39
references.pmid: 10628745